ATE398463T1 - Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten - Google Patents

Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten

Info

Publication number
ATE398463T1
ATE398463T1 AT01925021T AT01925021T ATE398463T1 AT E398463 T1 ATE398463 T1 AT E398463T1 AT 01925021 T AT01925021 T AT 01925021T AT 01925021 T AT01925021 T AT 01925021T AT E398463 T1 ATE398463 T1 AT E398463T1
Authority
AT
Austria
Prior art keywords
idephosphate
immuno
compositions
compositions containing
containing aminoalkyl
Prior art date
Application number
AT01925021T
Other languages
English (en)
Inventor
Sally Mossman
Lawrence Evans
Original Assignee
Corixa Corp
Antigenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Antigenics Inc filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE398463T1 publication Critical patent/ATE398463T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01925021T 2000-04-13 2001-04-13 Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten ATE398463T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19684600P 2000-04-13 2000-04-13

Publications (1)

Publication Number Publication Date
ATE398463T1 true ATE398463T1 (de) 2008-07-15

Family

ID=22727009

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925021T ATE398463T1 (de) 2000-04-13 2001-04-13 Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten

Country Status (7)

Country Link
EP (1) EP1385541B1 (de)
AT (1) ATE398463T1 (de)
AU (1) AU5162201A (de)
CA (1) CA2396762A1 (de)
DE (1) DE60134499D1 (de)
ES (1) ES2309064T3 (de)
WO (1) WO2001078777A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7030094B2 (en) 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1635766A4 (de) * 2003-06-06 2009-09-30 Agennix Inc Lactoferrin als adjuvans in krebs-vakzinen
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2007055952A2 (en) * 2005-11-03 2007-05-18 Wyeth Process for producing stable hiv th-ctl peptides
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2019175147A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against intra-abdominal infections
EA202192390A1 (ru) 2019-03-18 2021-12-03 Янссен Фармасьютикалз, Инк. Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
AU2020358862A1 (en) 2019-10-02 2022-04-14 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
EP4090363B1 (de) 2020-01-16 2024-09-04 Janssen Pharmaceuticals, Inc. Fimh-mutante, zusammensetzungen damit und deren verwendung
WO2022058945A1 (en) 2020-09-17 2022-03-24 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
EP4277921A1 (de) 2021-01-12 2023-11-22 Janssen Pharmaceuticals, Inc. Fimh-mutanten, zusammensetzungen damit und verwendung davon
WO2022208430A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.

Also Published As

Publication number Publication date
AU5162201A (en) 2001-10-30
ES2309064T3 (es) 2008-12-16
EP1385541B1 (de) 2008-06-18
EP1385541A4 (de) 2005-12-14
WO2001078777A2 (en) 2001-10-25
CA2396762A1 (en) 2001-10-25
DE60134499D1 (de) 2008-07-31
EP1385541A1 (de) 2004-02-04

Similar Documents

Publication Publication Date Title
ATE398463T1 (de) Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
HUP0301815A2 (hu) Fertżzż és egyéb betegségek kezelésére használható mono- és diszacharid alapú gyógyszerkészítmény és profilaktikus és terápiás kezelés
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
MX2008013993A (es) Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
MXPA06000619A (es) Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
EP1487273A4 (de) Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
NO20072526L (no) Halvfaste C-klasse immunstimulerende oligonukleotider
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MY125202A (en) Vaccine
MXPA06005639A (es) Adyuvante antimicrobiano.
GB0123580D0 (en) Vaccine
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
MY146106A (en) Antiallergic vaccine composition, method for its preparation and use in the treatment of allergic diseases
MX2021014353A (es) Adyuvantes de vacunas basados en ligandos de receptores tlr.
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
MY127452A (en) Vaccines.
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties